We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-2.86%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.1B
AUM Growth
-$432M
Cap. Flow
-$290M
Cap. Flow %
-26.37%
Top 10 Hldgs %
65.53%
Holding
227
New
63
Increased
36
Reduced
51
Closed
66

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$19.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.96M
3
MNKD icon
MannKind Corp
MNKD
+$4.94M
4
ESPR
Esperion Therapeutics
ESPR
+$3.17M
5
BNBX
BNB PLUS CORP
BNBX
+$2.81M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.35M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.2M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.96M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$2.32M
5
HURA
TuHURA Biosciences
HURA
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.87%
2 Financials 0.19%
3 Industrials 0.07%
4 Consumer Staples 0.03%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
76
Xenon Pharmaceuticals
XENE
$6.28B
$931K 0.08%
329,400
+21,800
+7% +$59.3K
PRTA icon
77
Prothena Corp
PRTA
$448M
$927K 0.08%
+24,730
New +$1.26M
PRTA icon
78
CALL
Prothena Corp
PRTA
$448M
$900K 0.08%
240
-759
-76% -$38.6K
BIIB icon
79
PUT
Biogen
BIIB
$30.4B
$879K 0.08%
+230
New +$73.8K
MBAI
80
Check-Cap
MBAI
$8.12M
$876K 0.08%
4,198
-739
-15% -$227K
IPCI
81
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$867K 0.08%
+108,364
New +$984K
TSRO
82
PUT
DELISTED
TESARO, Inc.
TSRO
$862K 0.08%
104
– –
TRAW icon
83
Traws Pharma
TRAW
$7.81M
$842K 0.08%
100
-50
-33% -$515K
TPST icon
84
Tempest Therapeutics
TPST
$13.9M
$840K 0.08%
205
+17
+9% +$71.3K
AIMT
85
PUT
DELISTED
Aimmune Therapeutics
AIMT
$840K 0.08%
+222
New +$7.16K
CTXR icon
86
Citius Pharmaceuticals
CTXR
$13.7M
$820K 0.07%
+8,405
New +$842K
TSRO
87
DELISTED
TESARO, Inc.
TSRO
$804K 0.07%
9,700
+6,200
+177% +$608K
CGRN
88
DELISTED
Capstone Green Energy Corporation Common Stock
CGRN
$758K 0.07%
+98,379
New +$876K
ESPR
89
CALL
DELISTED
Esperion Therapeutics
ESPR
$757K 0.07%
+115
New +$6.19K
TMBR
90
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$740K 0.07%
+448
New +$1.22M
AMAG
91
CALL
DELISTED
AMAG Pharmaceuticals
AMAG
$733K 0.07%
553
+299
+118% +$4.51K
FCSC
92
DELISTED
Fibrocell Science Inc.
FCSC
$733K 0.07%
+225,718
New +$1.97M
TSRO
93
CALL
DELISTED
TESARO, Inc.
TSRO
$704K 0.06%
85
-15
-15% -$1.47K
SLS icon
94
SELLAS Life Sciences
SLS
$1.98B
$687K 0.06%
1,749
-52
-3% -$25.1K
EIGR
95
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$684K 0.06%
1,633
-1,450
-47% -$518K
BIOC
96
DELISTED
Biocept, Inc.
BIOC
$668K 0.06%
+107
New +$846K
ACGN
97
DELISTED
Aceragen Inc
ACGN
$650K 0.06%
2,267
+1,126
+99% +$322K
SIOX
98
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$608K 0.06%
14,433
-65,887
-82% -$2.96M
ASXC
99
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$589K 0.05%
235
-29
-11% -$892
CYPH
100
Cypherpunk Technologies Inc
CYPH
$65.4M
$558K 0.05%
+8,935
New +$539K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sabby Management held 227 positions worth $1.1B, down 28% from $1.53B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $290M in Q4 2017, closing 66 positions and reducing 51 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $3.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 7.3% a quarter earlier, followed by Financials and Industrials.

Against the trend, Sabby Management opened a new position in Odonate Therapeutics, Inc. Common Stock worth $20.6M.

  • Sabby Management's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.
  • Sabby Management added most to Esperion Therapeutics in Q4 2017, an estimated $3.17M increase.
  • Sabby Management's biggest Q4 2017 reduction was Bristol-Myers Squibb, cutting an estimated $3.2M.
  • Sabby Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2017, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 66% of its $1.1B portfolio in Q4 2017.
  • Sabby Management opened 63 new positions and closed 66 in Q4 2017.
  • Sabby Management's portfolio value fell 28% quarter-over-quarter to $1.1B.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.